Outpatient Oncology Infusion Market Size & Growth Forecast 2027–2036, By Segments (Product, Therapy, Mode, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Outpatient Oncology Infusion Market size was around USD 3.1 Billion in 2026 and is slated to grow at 11.02% CAGR from 2027 to 2036, reaching USD 8.82 Billion by 2036. The industry revenue for 2027 is estimated at USD 3.4 Billion.
Get more details on this report
Request Free Sample ReportOutpatient Oncology Infusion Market Intelligence Snapshot
Regional Market Dynamics
- North America held 45.69% in 2026, supported by established oncology infrastructure, specialized outpatient facilities, advanced infusion therapies, and strong reimbursement frameworks.
- Asia Pacific is growing fastest as cancer care infrastructure, healthcare spending, infusion center availability, and demand for cost-efficient treatment settings expand.
Segment Momentum
- Infusion pumps held the largest 53.21% market share in 2026 and are also the fastest-growing product segment because they enable precise drug delivery, improve patient safety, and enhance clinical workflow efficiency in outpatient cancer care.
- The subcutaneous mode is the fastest-growing segment due to shorter, more convenient injection procedures that improve patient comfort, reduce chair time, and increase operational efficiency in outpatient infusion centers.
Market Expansion Drivers
- Rising global cancer prevalence driving outpatient infusion service expansion
- Shift toward cost-efficient outpatient care accelerating ambulatory oncology adoption
- Advancements in infusion pump technology enabling safer home-based oncology treatments
Leading Market Participants
- Leading companies in the outpatient oncology infusion market include B. Braun Melsungen AG (Germany), Baxter International Inc. (USA), Fresenius Kabi AG (Germany), ICU Medical Inc. (USA), Becton, Dickinson and Company (USA), Terumo Corporation (Japan), Medtronic plc (Ireland), Nipro Corporation (Japan), Teleflex Incorporated (USA), Moog Inc. (USA)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 3.1 Billion
- 2027 Estimated Market Size: USD 3.4 Billion
- Projected Market Size: USD 8.82 Billion by 2036
- Growth Forecast: 11.02% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Infusion Pumps (Product) | Immunotherapy (Therapy) | Intravenous (IV) (Mode) | Breast Cancer (Application)
- Emerging Opportunity Segment: Infusion Pumps (Product) | Immunotherapy (Therapy) | Subcutaneous (Mode) | Lung Cancer (Application)
Market Growth Drivers and Industry Trends
Rising global cancer prevalence driving outpatient infusion service expansion
Increasing cancer incidence worldwide is creating greater demand for accessible treatment facilities capable of delivering specialized therapies outside traditional hospital settings. The outpatient oncology infusion market growth is driven by expanding infusion services that allow patients to receive chemotherapy, immunotherapy, and other treatments in dedicated ambulatory environments. Healthcare providers are increasing outpatient capacity to accommodate growing treatment requirements while improving convenience for patients undergoing repeated therapy sessions.
Shift toward cost-efficient outpatient care accelerating ambulatory oncology adoption
Healthcare systems are increasingly moving toward lower-cost care models that maintain treatment quality while reducing dependence on inpatient facilities. The outpatient oncology infusion market will drive growth as ambulatory centers provide more efficient treatment delivery through specialized facilities designed for oncology patients. This transition supports improved resource allocation, shorter hospital stays, and greater flexibility for patients requiring ongoing infusion-based therapies.
Advancements in infusion pump technology enabling safer home-based oncology treatments
Innovations in infusion devices are improving treatment control, portability, and safety, enabling more oncology therapies to be administered in home-based settings. The outpatient oncology infusion market will boost adoption as advanced infusion pumps support accurate medication delivery and provide greater flexibility for patients receiving long-duration treatments. Enhanced device capabilities are helping healthcare providers explore alternative treatment models that extend oncology care beyond traditional clinical environments.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global cancer prevalence driving outpatient infusion service expansion | 2.2% | High | North America, Europe | High | Near Term |
| Shift toward cost-efficient outpatient care accelerating ambulatory oncology adoption | 1.9% | High | North America, Asia Pacific | High | Near Term |
| Advancements in infusion pump technology enabling safer home-based oncology treatments | 1.6% | Moderate | Europe, North America | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the outpatient oncology infusion market in 2026, accounting for a 45.69% share. The region's leadership is supported by its well-established oncology care infrastructure, high availability of specialized outpatient treatment facilities, and strong adoption of advanced infusion therapies. Growing cancer incidence, combined with a broader shift toward outpatient care, has encouraged healthcare providers to expand infusion services outside traditional inpatient settings. The region also benefits from established reimbursement frameworks, specialized clinical expertise, and continued investment in healthcare infrastructure, enabling patients to receive chemotherapy, immunotherapy, and other infusion-based treatments in more convenient ambulatory environments.
Asia Pacific (Fastest-Growing Region)
The Asia Pacific market is positioned as the fastest-growing regional market, driven by expanding cancer care infrastructure and increasing access to specialized treatment services. Rising awareness of cancer screening and treatment, growing healthcare expenditure, and improving medical facilities are supporting the expansion of outpatient oncology services across the region. In addition, the growing patient population and increasing demand for cost-efficient treatment settings are encouraging healthcare systems to shift suitable oncology procedures toward outpatient facilities. Improvements in hospital capacity, infusion center availability, and healthcare access are expected to further strengthen regional adoption.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Community Infusion ExpansionThe U.S. outpatient oncology infusion market continues expanding community-based infusion centers that improve treatment accessibility while reducing pressure on hospitals. Healthcare providers in the U.S. increasingly adopt coordinated care models supported by digital scheduling and patient monitoring capabilities.
Germany 🇩🇪
Integrated Cancer PathwaysGermany emphasizes outpatient oncology infusion services that align with multidisciplinary cancer treatment pathways and coordinated specialist care. Providers across Germany focus on operational efficiency, standardized treatment delivery, and improved patient convenience within ambulatory settings.
Japan 🇯🇵
Patient-Centered Treatment AccessJapan continues strengthening outpatient oncology infusion capacity to accommodate increasing demand for long-term cancer therapies. Healthcare providers in Japan prioritize efficient appointment management, supportive care services, and treatment environments that improve patient experience during repeated infusion visits.
South Korea 🇰🇷
Digital Oncology CoordinationSouth Korea expands outpatient oncology infusion services through digitally connected healthcare systems that support treatment planning and patient follow-up. Oncology providers in South Korea focus on improving clinical coordination while optimizing infusion center utilization and patient care efficiency.
France 🇫🇷
Ambulatory Oncology OptimizationFrance continues encouraging outpatient oncology infusion models that reduce inpatient dependence while maintaining continuity of cancer care. Healthcare organizations in France emphasize coordinated treatment scheduling and supportive clinical services that enhance patient management throughout therapy cycles.
Italy 🇮🇹
Regional Care AccessibilityItaly strengthens outpatient oncology infusion services by improving access across regional healthcare facilities and specialized treatment centers. Providers in Italy focus on expanding ambulatory cancer care capacity while improving operational efficiency and continuity for patients receiving repeated infusion therapies.
Segment Leadership and Growth Trends
Outpatient Oncology Infusion Market Share (%), by Product, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Infusion Pumps (Largest & Fastest-Growing Segment)
The outpatient oncology infusion market was led by the infusion pumps segment, which held the largest share of 53.21% in 2026 while also emerging as the fastest-growing segment. Infusion pumps are central to outpatient cancer treatment because they deliver precise medication dosages, support controlled administration of complex oncology therapies, and improve patient safety throughout infusion procedures. The increasing shift toward ambulatory cancer care, combined with demand for accurate drug delivery and enhanced clinical workflow efficiency, continues to reinforce the segment's dominant position and sustained growth.
Therapy Segment Analysis: Immunotherapy (Largest & Fastest-Growing Segment)
Immunotherapy accounted for the largest share of 37.26% in 2026 and simultaneously represents the fastest-growing therapy segment. Its expanding adoption reflects the growing preference for treatments that harness the body's immune system to target cancer while offering improved outcomes for a broad range of malignancies. Continuous advances in immuno-oncology, expanding clinical indications, and increasing integration of these therapies into outpatient treatment settings continue to strengthen demand. Within the outpatient oncology infusion market, the segment benefits from sustained innovation and the broader transition toward personalized cancer care.
Mode Segment Analysis: Intravenous (IV) (Largest Segment) vs Subcutaneous (Fastest-Growing Segment)
The intravenous (IV) mode held the largest share of 34% in 2026, reflecting its established role in administering a wide range of oncology therapies that require controlled infusion, dose flexibility, and close clinical monitoring. Healthcare providers continue to rely on intravenous delivery for complex treatment regimens because it supports accurate administration and accommodates diverse therapeutic protocols across outpatient infusion centers.
Within the outpatient oncology infusion market, the subcutaneous mode is the fastest-growing segment as newer therapies are increasingly formulated for administration through shorter and more convenient injection procedures. This approach improves patient comfort, reduces chair time, and enhances operational efficiency for outpatient facilities. Growing emphasis on patient-centered care and optimized treatment delivery is expected to support continued adoption of subcutaneous oncology therapies.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Infusion Pumps, Intravenous Sets, IV Cannulas, Needleless Connectors | Infusion Pumps | Infusion Pumps |
| Therapy | Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy | Immunotherapy | Immunotherapy |
| Mode | Intramuscular (IM), Intravenous (IV), Subcutaneous, Others | Intravenous (IV) | Subcutaneous |
| Application | Lung Cancer, Liver Cancer, Breast Cancer, Prostate Cancer, Others | Breast Cancer | Lung Cancer |
Competitive Landscape and Market Positioning
Top players in the outpatient oncology infusion market:
- B. Braun Melsungen AG (Germany)
- Baxter International, Inc. (USA)
- Fresenius Kabi AG (Germany)
- ICU Medical, Inc. (USA)
- Becton Dickinson and Company (USA)
- Terumo Corporation (Japan)
- Medtronic plc (Ireland)
- Nipro Corporation (Japan)
- Teleflex Incorporated (USA)
- Moog, Inc. (USA)
Care delivery models are transforming the competitive dynamics of the outpatient oncology infusion market as providers seek to balance treatment accessibility with increasingly personalized cancer care. Healthcare organizations are differentiating through coordinated clinical services, streamlined scheduling, and multidisciplinary care pathways that improve the patient experience while supporting complex infusion regimens. Competition is also influenced by the growing adoption of digital care management tools, remote patient monitoring, and standardized treatment workflows that enhance continuity of care beyond the infusion center. Operational efficiency, clinical expertise, and the ability to accommodate evolving therapeutic protocols are becoming more significant competitive advantages than treatment capacity alone.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| B. Braun Melsungen AG (Germany) | |||||||
| Baxter International Inc. (USA) | |||||||
| Fresenius Kabi AG (Germany) | |||||||
| ICU Medical Inc. (USA) | |||||||
| Becton Dickinson and Company (USA) | |||||||
| Terumo Corporation (Japan) | |||||||
| Medtronic plc (Ireland) | |||||||
| Nipro Corporation (Japan) | |||||||
| Teleflex Incorporated (USA) | |||||||
| Moog Inc. (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Evolent Health | Nov-25 | Evolent Health partnered with the American Oncology Network to launch an operational care delivery model utilizing real-time electronic health record data. This initiative identifies pathway-adherent care and gold-card providers to remove prior authorization requirements, accelerating treatment initiation and reducing administrative burdens in clinical workflows. |
| Penlon | May-25 | Penlon expanded its clinical delivery portfolio with the introduction of the HP TCi Syringe Pump, SYS-56, and SYS-70 systems. These devices provide clinicians with enhanced precision, safety features, and simplified control for intravenous anesthesia and medication delivery, strengthening the company's product offerings and commercial sales prospects within clinical care settings. |
| ICU Medical Inc. | Apr-25 | ICU Medical Inc. secured 510(k) regulatory clearance from the U.S. Food and Drug Administration for the Plum Solo precision intravenous pump. The company also obtained clearance for updated versions of the Plum Duo precision intravenous pump and LifeShield infusion safety software, bolstering its competitive positioning in the infusion technology sector. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Outpatient Oncology Infusion Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Payer Type | Commercial Insurance, Government Insurance, Self-Pay, Other Payers |
| Care Setting | Hospital Outpatient Departments, Physician Offices, Ambulatory Infusion Centers, Home Infusion |
| Treatment Duration | Short-Duration Infusions, Intermediate-Duration Infusions, Long-Duration Infusions |
Outpatient Oncology Infusion Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Site-of-Care Transformation |
|
| Infusion Capacity & Utilization Optimization |
|
| Ambulatory Infusion Network Strategy |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the outpatient oncology infusion market generate?
How is the outpatient oncology infusion industry size expected to evolve during the forecast period?
How are healthcare delivery models reshaping demand in the outpatient oncology infusion market?
Why are advanced infusion technologies influencing outpatient oncology treatment expansion?
Why do infusion pumps lead the outpatient oncology infusion market?
Which administration mode is growing fastest in the outpatient oncology infusion market?
Why does North America lead the outpatient oncology infusion market?
How is Asia Pacific driving growth in outpatient oncology infusion services?
What are the prominent companies operating in the outpatient oncology infusion landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization